Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$4.38 USD
-0.19 (-4.16%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $4.39 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DTIL 4.38 -0.19(-4.16%)
Will DTIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DTIL
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Qiagen (QGEN) Matches Q2 Earnings Estimates
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates
Other News for DTIL
Precision BioSciences GAAP EPS of -$2.13 misses by $0.56
Precision BioSciences Q2 2025 Earnings: EPS of ($2. ...
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business ...
Precision BioSciences Q2 2025 Earnings Preview
Precision BioSciences reports safety, efficacy data for ELIMINATE-B trial cohort